Frankfurt am Main, Germany

Paul Habermann

USPTO Granted Patents = 34 


 

Average Co-Inventor Count = 2.9

ph-index = 11

Forward Citations = 499(Granted Patents)


Location History:

  • Taunus, DE (1996)
  • Eppstein am Taunus, DE (1994 - 1997)
  • Eppstein/Taunus, DE (1992 - 2005)
  • Eppstein, DE (1999 - 2011)
  • Frankfurt-am-Main, DE (1993 - 2022)

Company Filing History:


Years Active: 1992-2022

where 'Filed Patents' based on already Granted Patents

34 patents (USPTO):

Title: Innovations by Paul Habermann in Biomedical Research

Introduction

Paul Habermann, a prominent inventor located in Frankfurt am Main, Germany, has made significant contributions to the field of biomedical research, evidenced by his 34 patents. His work primarily focuses on innovative approaches to treating various metabolic disorders and joint diseases.

Latest Patents

Among his latest patents, one notable invention is the development of polypeptide variants of human fibroblast growth factor 21 (FGF21). This invention also includes fusion molecules and nucleic acid products that could be utilized as medicaments for conditions like obesity, diabetes mellitus, and metabolic syndrome. Another recent innovation involves a CD-RAP precursor protein designed for the efficient manufacture of native CD-RAP. This invention presents a composition including CD-RAP and positively charged amino acids, which is aimed at treating cartilage diseases. Additionally, he has patents on liposomal compositions that encapsulate CD-RAP or its variants, focused on the treatment and prevention of joint diseases.

Career Highlights

Throughout his career, Paul has worked with various influential companies, including Hoechst Aktiengesellschaft and Sanofi-Aventis Deutschland GmbH. His contributions to these organizations have facilitated advancements in medical and pharmaceutical applications associated with his patented technologies.

Collaborations

Paul collaborated with esteemed colleagues such as Peter Crause and Dominique Tripier. Together, they have worked on innovative projects that enhance the therapeutic landscape for metabolic and joint-related health challenges.

Conclusion

Paul Habermann's innovations reflect his dedication to addressing critical health issues through scientific research and development. With a substantial number of patents and impactful collaborations, he continues to drive further advancements in the biomedical field, potentially improving the quality of life for many individuals suffering from metabolic and joint disorders.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…